OncLive TV

Ray McDermott, MB, BCh, BAO, PhD, MBA, FRCPI, discusses the design of the DASL-HiCAP trial in high-risk prostate cancer.

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Patricia Pautier, MD, discusses the results of the phase 2 LMS-02 trial with doxorubicin and trabectedin in ​uterine and soft tissue leiomyosarcoma.

Weijing Sun, MD, FACP, discusses remaining challenges in the first-line treatment of patients with gastric cancer.

Charu Aggarwal, MD, MPH, discusses investigational biomarkers in lung cancer.

Nilofer S​aba Azad, MD, discusses treatment considerations in right- versus left-sided colorectal cancer.

John L. Marshall, MD, discusses ​sequencing challenges in colorectal cancer.

Salvatore Siena, MD, discusses the rationale for the phase 2 DESTINY-CRC01 trial in metastatic colorectal cancer.

Nilofer S​aba Azad, MD, discusses remaining challenges in colorectal cancer.

Gary K. Schwartz, MD, discusses future research efforts in the field of sarcoma.

Prithviraj Bose, MD, discusses current treatment options for essential thrombocythemia.

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Seema A. Bhat, MD, discusses the potential for time-limited combination regimens in chronic lymphocytic leukemia.

Shuo Ma, MD, PhD, discusses the need to develop novel agents to treat patients with chronic lymphocytic leukemia who develop resistance to BTK inhibitors.

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Carlo Visco, MD, discusses the results of early relapse versus late relapse in the MANTLE-FIRST study with ibrutinib versus chemoimmunotherapy in mantle cell lymphoma.

Neal D. Shore, MD, FACS, discusses the results from the phase 3 HERO trial with relugolix in men with advanced prostate cancer.

Scott Kopetz, MD, PhD, FACP, discusses the design of the phase 3 BEACON CRC trial in metastatic colorectal cancer.

Tanios S. Bekaii-Saab, MD, FACP, discusses the emergence of targeted therapy in colorectal cancer.

Edward Chu, MD, MMS, discusses the importance of identifying patients with microsatellite instability–high metastatic colorectal cancer.

Aziz Nazha, MD, discusses the potential role of ropeginterferon alfa-2b in polycythemia vera.

Robert G. Maki, MD, PhD, FACP, FASCO, discusses the potential utility of immunotherapy in sarcoma.

Seema A. Bhat, MD, emerging targeted therapies in chronic lymphocytic leukemia.

Maha Hussain, MD, FACP, FASCO, discusses the design of the phase 3 PROSPER trial in patients with nonmetastatic castration-resistant prostate cancer.

Derek C. Galligan, MD, discusses the utility of up-front high-intensity therapy for patients with multiple myeloma.

Nicole Concin, MD, discusses the patient population that enrolled in the phase ​1b/2 LIO-1 trial in advanced gynecologic malignancies.

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Rebecca Silbermann, MD, MMS, discusses the role of disease biology in multiple myeloma. 

Matthew S. Davids, MD, MMSc, discusses selecting between continuous and time-limited therapy in chronic lymphocytic leukemia.

Caroline Farrington, PhD, discusses the importance of genetic testing in colorectal cancer.